Clinical Trial Update: ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon [Phase 2]

View source ↗

Summary

Phase 2 trial in people with Type 1 diabetes completed, evaluating ZP4207 (dasiglucagon) for its pharmacokinetics and pharmacodynamics compared with marketed gl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• GLUCAGON (GLUCAGON)
• ZP4207 (Dasiglucagon) (dasiglucagon)

Snippet

Sponsor: Zealand Pharma | Conditions: Diabetes Mellitus Type 1 | Phase 2 | Status: COMPLETED